Lexaria Bioscience Corp. (LEXX)
2025-05-31 | 2024-11-30 | |||
|---|---|---|---|---|
| Revenue | 174,000 | 183,923 | ||
| Cost of goods sold | - | 2,720 | ||
| Gross profit | 174,000 | 181,203 | ||
| Research and development | 2,717,501 | 1,953,220 | ||
| General and administrative | 1,206,920 | 918,690 | ||
| Total operating expenses | 3,924,421 | 2,871,910 | ||
| Loss from operations | -3,750,421 | -2,690,707 | ||
| Unrealized loss on marketable securities | -40,375 | -15,932 | ||
| Interest income | 190 | 11 | ||
| Total other income (loss) | -40,185 | - | ||
| Other nonoperating income (expense) | - | -15,921 | ||
| Net loss | -3,790,606 | -2,706,628 | ||
| Less net loss attributable to non-controlling interest | -1,514 | -2,929 | ||
| Net loss attributable to lexaria shareholders | -3,789,092 | -2,703,699 | ||
| Foreign currency translation adjustment | 37,173 | -3,175 | ||
| Total comprehensive loss | -3,751,919 | -2,706,874 | ||
| Basic and diluted loss per share | -0.21 | -0.16 | ||
| - basic and diluted | 18,298,309 | 16,668,513 | ||